Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation was incorporated in May 1995 under the Canada Business Corporations Act. The company's initial purpose was to acquire DMS Pharmaceutical Inc., which had been conducting research and development since 1989 on diagnostics and drugs for brain disorders and diseases of the aged, with a focus on Alzheimer's disease. In 2015, Nymox Pharmaceutical Corporation changed its domicile to The Bahamas. The company has funded its operations and projects primarily through the sale of its common stock. Nymox's common shares traded on the Nasdaq Stock Market from December 1, 1996, to July 9, 2023. Shares then traded on the Over the Counter (OTC), Pink Sheets until June 2024, and subsequently began trading on the Over the Counter QB (OCTQB) Venture Market in December 2024, where they have traded since. Nymox's common shares also traded on the Montreal Exchange from December 18, 1995, to November 19, 1999. As of December 31, 2024, Nymox has raised over $202 million since its incorporation in May 1995, through the issuance of common stock or securities exercisable for common stock. Nymox has one wholly-owned subsidiary, Nymox Corporation. Nymox Corporation opened an office in California (USA) in August 2018, where it conducts some research and development and maintains all Quality Assurance activities for its product(s).